Abstract
HSPCs. This would be a major step forward in developing effective anti-AML therapeutic antibodies with reduced hematologic toxicity.
Abadir E, Gasiorowski RE, Lai K, Kupresanin F, Romano A, Silveira PA, Lo TH, Fromm PD, Kennerson ML, Iland HJ, Ho PJ, Hogarth PM, Bradstock K, Hart DNJ, Clark GJ
VIEW FULL ARTICLEJournal Molecular oncology
Published 20 Aug 2019
Volume 13
ISSUE 10
Pagination 2107-2120
DOI 10.1002/1878-0261.12549
HSPCs. This would be a major step forward in developing effective anti-AML therapeutic antibodies with reduced hematologic toxicity.